EMA Panel Rejects Abaloparatide for Osteoporosis EMA Panel Rejects Abaloparatide for Osteoporosis

The CHMP has rejected the marketing application for abaloparatide (Radius Health) subcutaneous injection for postmenopausal women with osteoporosis at increased risk for fracture.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news